BioTuesdays

Author - Melane Sampson

Amryt-Logo
Markets

SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

February 16, 2021
Cycle-Therapeutics-Logo
Markets

Maxim ups Cyclo Therapeutics PT to $25 from $12

Maxim Group more than doubled its price target for Cyclo Therapeutics (NASDAQ:CYTH) to $25 from $12, citing updates from the Phase 1 and Phase 1/2 clinical programs for Trapsol Cyclo (TC) in Neimann-Pick Type C (NPC)...

February 9, 2021
Aditxt-Logo
Markets

Dawson Jones starts Aditxt Therapeutics at buy; PT $14

Dawson Jones Securities initiated coverage of Aditxt Therapeutics (NASDAQ:ADTX) with a “buy” rating and $14 price target. The stock closed at $3.34 on Feb. 3. Aditxt has developed a unique antibody test that measures a...

February 4, 2021
Cullinan-Oncology-Logo
Markets

SVB Leerink starts Cullinan at OP; PT $52

SVB Leerink initiated coverage of Cullinan Management (NASDAQ:CGEM) with an “outperform” rating and $52 price target. The stock closed at $33.77 on Feb. 1. Cullinan is leveraging a unique “Hub-and-Spoke”...

February 2, 2021
Kardium
Developments

Kardium raises $115-million financing round

Closely held Kardium raised $115-million in a new financing round led by Fidelity Management & Research, together with follow-on participation by funds and accounts advised by T. Rowe Price Associates. The new...

January 25, 2021
mdbriefcase-thinkresearch_logo
Developments

Think Research to acquire MDBriefCase Group

Think Research (TSXV:THNK) agreed to acquire closely held MDBriefCase Group, a portfolio company of Persistence Capital Partners, for $25.3-million, mostly in stock. The transaction, which is expected to close in the...

January 20, 2021